Query our full-text historical index across market dispatches, earnings reports, central bank policies, and financial analyses.
GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.
AstraZeneca is advancing a portfolio of targeted cancer therapies to protect oncology margins and achieve its ambitious 2030 revenue targets.
Swiss pharmaceutical powerhouse Roche is ramping up its oncology pipeline, targeting critical gaps in lung cancer care across key emerging markets.